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Background. This study aimed to analyse the most common current indications for total pancreatectomy (TP) at a high-volume
pancreas center. Method. Prospectively collected data on indications and short-term outcome of all TP’s performed from January
2004 until June 2008 were analysed. Results. The total pancreatectomies (TP) were 63, i.e., 6.7% of all pancreatic procedures
(n = 948). Indications for TP were classiﬁed into 4 groups: tumors of advanced stage, n = 23 (36.5%), technical problems due
to soft pancreatic tissue, n = 18 (28.6%), troubles due to perioperative surgical complications, n = 15 (23.8%), and therapy-
resistant pain due to chronic pancreatitis, n = 7 (11.1%). Surgical complications occurred in 23 patients (36.5%). The mortality
in elective TP was 6.25%. Median postoperative stay was 21 days. Mortality, morbidity and the other perioperative parameters
diﬀered substantially according to the indication for pancreatectomy. Conclusion. Total pancreatectomy is deﬁnitely indicated for
a limited range of elective and emergency situations. Indications can be: size or localisation of pancreatic tumor, trouble, technical
diﬀuculties and therapy-refractory pain in chronic pancreatitis. A TP due to perioperative complications (troubles) after pancreatic
resections is doomed by extremely high morbidity and mortality and should be avoided.
1.Introduction
The complete removal of the pancreas has been a topic of
controversial discussions ever since surgeons realized that it
was feasible. The sporadic reports of total pancreatectomy
(TP) in the 1940s and 1950s of the twentieth century grew
to a frank enthusiasm about the potential advantages of the
procedure with the accumulation of surgical experience in
the 1970s but were about to vanish later due to the negative
metabolic consequences of the operation.
The complete removal of the gland has already been
established as a potential option in the treatment of locally
advancedpancreaticcancer,multifocalorrecurrentexocrine,
and endocrine tumors [1–4]. Troubles, such as perioperative
complications arising from pancreatic anastomotic leakage
with or without bleeding or apoplexy of the pancreatic
remnant, may require complete removal of the remaining
o r g a ni na ne m e r g e n c ys i t u a t i o n[ 5, 6]. Extremely soft
pancreatic tissue has been described as a technical reason
for TP during the primary operation to prevent a high-
risk pancreatic anastomosis [7]. Therapy refractory pain
associated with chronic pancreatitis has been reported as a
further indication for TP [8–13].
Despite increasing demand for TP and increasing rate of
its performance at large pancreas centres recently, reports in
the literature on its current indications and results remain
scarce [14, 15].
The aim of this study was to analyse the current indi-
cations and the outcome between the diﬀerent indications
for TP at a single high-volume institution and determine the
current place of TP in the spectrum of pancreatic resections.
2. Patients andMethods
All cases of TP were analysed within the prospectively
managed pancreas data bank at the Department of General2 HPB Surgery
and Visceral Surgery, St. Josef Hospital Bochum, Germany.
All resections were performed by three experienced pan-
creatic surgeons. The set of data available for every patient
included detailed information on all preoperative diagnostic
procedures, perioperative parameters, and postoperative
complications, as well as strict follow-up documentation.
The preoperative risk assessment was graded according to
the American Society of Anaesthesiologists classiﬁcation
(ASA). Operation time, perioperative blood loss, necessity
of red blood cell transfusions, and postoperative hospi-
tal stay were evaluated. Postoperative complications were
determined and categorised into major and minor sur-
gical complications and nonsurgical ones. Major compli-
cations comprised biliary leakage, postoperative bleeding,
intraabdominal abscess, and burst abdomen. Minor surgical
complications included delayed gastric emptying, cholan-
gitis, chylous ﬁstula, and wound infection. Nonsurgical
complications were deﬁned as complications within 30
days of surgery or during the hospital stay that were not
directly related to the surgical procedure, for example,
pneumonia, urinary tract infection, or systemic infections
not related to the surgical procedure (e.g., central venous
infection). Any death during the hospital stay or within the
ﬁrst 30 days after operation was deﬁned as postoperative
mortality.
2.1. Statistics. Statistical analysis was performed using the
SPSS 16 software package (SPSS Inc., Chicago, IL, USA). All
data are presented as median with interquartile range and
minimal and maximal values, which are shown in the ﬁgures
as box-and-whisker plots, respectively. For comparison of
quantitative variables were used the nonparametric Mann-
Whitney and Kruskal-Wallis tests. Two-sided P values were
always computed, and an eﬀect was considered statistically
signiﬁcant at P<. 05.
3. Results
3.1. Study Population. During the study period of 54 months
(January 2004–June 2008) 948 patients underwent surgery
for pancreatic disease, of which 599 (63.2%) pancreatic
resectional procedures. The total pancreatectomies were
63, that is, 6.7% of all pancreatic procedures. They were
performed in 34 (54%) males and 29 (46%) females at
a median age of 69 (38–87) years. In 45 cases (71.4%) a
TP was performed as a primary procedure; in the rest 18
patients it was a completion pancreatectomy. A splenectomy
was performed in 45 patients; in eighteen the spleen was
preserved. Twenty-ﬁve patients (39.7%) were classiﬁed as
A S AI- I I ,w h i l e3 8( 6 0 . 3 % )w e r ec a t e g o r i z e da sA S Ac l a s s
III-IV. Substantial cardiac comorbidity was present in 13
cases (21%), pulmonary in 8 (12.7%), and renal in 4
(6.3%). Insulin-dependent diabetes mellitus was present in
11 patients (17.5%).
3.2. Indications for Total Pancreatectomy. The indications
for a TP were grouped to the “Four T’s” categories as
summarized in Table 2.
3.2.1. Tumors. Twenty-three patients (36.5%) underwent TP
for malignancy. In 22 cases it was a primary operation
and in one patient with a recurrent intraductal papillary-
mucinous cancer of the head after left resection a completion
pancreatectomy was performed. In 13 cases the main reason
for total pancreatectomy was the size of the tumor, which
spread over the most of the pancreas—there were 10 T3
tumors and 3 T4 tumors. There was also one patient with
a T3 carcinoma of the distal hepatic duct and a positive
resection margin on the frozen section—a total pancreate-
ctomy was necessary in that case too. In 8 cases multifocal
cancer was found—3 patients had a multicentric intraductal
papillary-mucionous carcinoma (all T2), 3 patients suﬀered
amultifocalpancreaticadenocarcinoma(oneofthemT2and
the other two T3), one patient had simultaneously a cancer
of the papilla (T3) and an adenocarcinoma of the pancreatic
body (T2), and one patient had a cystadenocarcinoma of the
pancreatic head (T3) and a simultaneous undiﬀerentiated
neuroendocrine cancer in the pancreatic body. There was
only one small T1 cancer of the pancreatic head for which
a total pancreatectomy was performed, because of the
subtotal atrophy of the rest pancreas due to a severe chronic
pancreatitis with preoperatively existing insulin-dependent
diabetes mellitus and a severe exocrine insuﬃciency. There
were twelve multivisceral resections (n = 12/23, 52%) and
four vessel reconstructions in this group (4/23, 17.4%). 3
patients from this group suﬀered from an endocrine and
2 patients from an exocrine insuﬃciency of the pancreas
preoperatively.
3.2.2. Technical Problems. Eighteen patients (28.6%) under-
went total pancreatectomy due to technical reasons, that is,
very soft and fatty pancreatic tissue in the remnant. In 13
of those patients the diagnosis was a small cancer of the
pancreatic head (six T1 and seven T2), two patients had a
T2 cancer of the distal common bile duct, another patient
had a benign cystadenoma in processus uncinatus, and there
were two cases of intraductal papillary mucinous adenoma
in the pancreatic head. There were no multivisceral and no
vessel resections in this group. Preoperatively 5 patients had
an endocrine and 1 patients also an exocrine dysfunction of
the pancreas.
3.2.3. Troubles in the Perioperative Period. Fifteen patients
(23.8%) underwent total pancreatectomy because of either
early postoperative or intraoperative troubles, that is, com-
plications. Twelve patients underwent a completion pancre-
atectomy because of postoperative complications after pan-
creatic resections of the head or tail: in 8 cases that was insuf-
ﬁciencyofthepancreaticanastomosis/stumpwithadditional
postoperative intraabdominal bleeding in 8 patients; in 2
cases pancreatectomy was necessary because of necrotising
pancreatitis of the pancreatic remnant with sepsis, and in 2
patients because of failure of the biliodigestive anastomosis
with biliary peritonitis. In three patients the decision to
perform a total pancreatectomy was made intraoperatively
in an emergency situation due to iatrogenic perforation of
the duodenum during ERCP, profuse bleeding of a duodenalHPB Surgery 3
carcinoma, and a bleeding of a giant pseudocyst of the
pancreatic head with a coagulation disorder. There were
n = 5/15, 33% multivisceral resections, and n = 3/15,
20% portal vein reconstructions in this group. 4 patients had
an endocrine and 1 patient an exocrine insuﬃciency of the
pancreas.
3.2.4. Therapy-Refractory Pain. Seven patients (11.1%) suf-
fered from a disabling therapy-resistant pain due to severe
chronic pancreatitis with small duct disease. In two patients
pancreatectomy was the primary intervention—the ﬁrst
one had a total atrophy of the pancreatic tail, and the
second one presented intraoperatively with a large tumor
mass, where a malignancy was suspected. In the other ﬁve
cases a completion pancreatectomy was carried out fol-
lowing prior resective pancreatic surgery without adequate
alleviation of pain (two cases after left resection, three
casesafterpancreaticoduodenectomy).All7patientssuﬀered
already preoperatively from severe endocrine and exocrine
insuﬃciency and all of them were analgesic drug addicts.
Multivisceral resections were necessary in two patients with
inﬂammatory stenosis of the colon. Also there were three
cases (43%) with portal vein reconstruction.
A total of 17 (27%) multivisceral resections were carried
out. There was one total gastrectomy, ten portal vein
resections with direct anastomosis, one resection of the
common hepatic artery and reconstruction with the splenic
artery, ﬁve left or right hemicolectomies, and one left adrenal
resection.
3.3. Intraoperative Parameters. Median operation time for
the whole group was 420min; the median intraoperative
blood loss was 800mL. Blood transfusions were necessary
in 29 (46%) patients. The duration of the surgical proce-
dure was signiﬁcantly shorter in patients with troubles as
an indication for pancreatectomy with a median time of
210min compared to all other indications with a median
of 448min (P = .001) (Figure 1). At the same time the
median intraoperative blood loss in the “troubles” group
was with 1500mL signiﬁcantly higher than that in patients
pancreatectomized because of tumors (800mL, P = .002),
soft pancreas (600mL, P = .001), or chronic pancreatitis
(600mL, P = .009). Pancreatectomies in the soft pancreas
group tended to be performed with less blood loss than
those in tumor patients, P = .043 (Figure 2). Respectively,
transfusion of red blood cell units was also the highest in the
“troubles”groupwithamedianof15RBCunitscomparedto
pancreatectomy due to other indications where the median
was zero RBC units (P = .001) (Figure 3).
3.4. Postoperative Morbidity. Major postoperative complica-
t i o n s ,e i t h e rs u r g i c a lo rn o n s u r g i c a l ,o c c u r r e di n3 2( 5 0 . 8 % )
patients. A total of 23 patients (36.5%) developed one or
more postoperative surgical complications. The spectrum
of minor surgical complications included delayed gastric
emptying, cholangitis, wound infection, and chylous ﬁstula.
The most often one was delayed gastric emptying—it
occurred in nine (14.3%) of the pancreatectomised patients.
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Figure 1: Operation time according to indications: (1) tumor,
(2) technical, (3) trouble, (4) therapy-refractory pain, ∗group 3
signiﬁcant shorter operation time compared to all others, P = .001.
Cholangitis developed postoperatively three (4.7%) patients.
A wound infection was observed in 4 (6.3%) cases and a
chylous ﬁstula appeared in 3 (4.8%) patients.
The following major surgical complications were
observed: ﬁve patients developed an intraabdominal
abscess. In three cases the abscess was situated in the
upper left abdominal quadrant after splenectomy, another
two were found in the left paracolic region. All abscesses
were successfully treated via CT-guided drainage. Three
patients with emergency completion pancreatectomy
suﬀered an acute postoperative erosion bleeding—in
two cases a hemorrhage from the splenic artery, and in
the other one from the left gastric artery. Two of these
patients needed multiple reoperations. All of those three
patients died due to the early or late consequences of the
hemorrhagic shock. Three other patients with completion
pancreatectomies were reoperated because of failure of the
biliodigestive anastomosis. One of those patients developed
a malignant postoperative arrhythmia, underwent a
pacemaker implantation, but progressed to liver and renal
failure with a fatal outcome. Two patients were treated for
a wound dehiscence, whereas one of them died due to a
progressive multiple organ failure.
The nonsurgical complications comprised of urinary
tract infections (most common with 11.1%, 7 patients),
2 cases of pneumonia—one of those patients died due to
multiple lung abscesses with respiratory failure and sepsis
with multiorgan failure, a pseudomembranous colitis in one
patient. One patient died of an acute myocardial infarction.4 HPB Surgery
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Figure 2: Intraoperative blood loss according to indications: (1)
tumor, (2) technical, (3) trouble, (4) therapy-refractory pain,
∗group 3 signiﬁcant higher blood loss compared to all others, P<
.009 in all cases, ∗∗group1 > group2, P = .043.
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Figure 3: Intraoperative transfused RBC units according to indica-
tions: (1) tumor, (2) technical, (3) trouble, (4) therapy-refractory
pain, ∗group 3 signiﬁcant more transfused RBC units than all other
groups, P = .001.
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Figure 4: Postoperative stay in 53 patients who survived TP is
according to indications: (1) tumor, (2) technical, (3) trouble, (4)
therapy-refractory pain, ∗group 3 signiﬁcant longer hospital stay
compared to 2 (P = .04) and group 4 (P = .01), ∗∗group 4 shorter
stay compared to group 1, P = .04.
Two patients developed renal failure, which was successfully
treated by means of hemoﬁltration.
3.5. Hospital Stay and Mortality. Median hospital stay of all
surviving patients (n = 53) after TP was 21 days (min–
max range 7–108 days). The surviving patients from the
“troubles” group had the longest postoperative hospital stay
withamedianof48days,whichwassigniﬁcantlylongerthan
the median of all other groups, 20 days, P = .035 (Figure 4).
Ten patients (15.9%) died in the postoperative period.
Five (7.9%) of them died as a consequence of major surgical
complications directly related to the operation, as described
above. One patient died of a severe pneumonia with
lung abscesses, another one due to myocardial infarction.
Another patient died because of thoracic hemorrhage after
complicated chest tube insertion for pleural eﬀusion during
her stay at the intensive care unit. Two more patients died of
multipleorganfailureduetoMRSAsepsis.Sevenoftheseten
patients were preoperatively classiﬁed ASA IV and the other
three were ASA III.
The highest mortality (7/15, 47%) was found in the
group of patients who underwent TP because of troubles.HPB Surgery 5
Three patients died in the “tumor” group, 3/23, 13%.
There was no perioperative or late mortality in patients
with therapy-refractory chronic pancreatitis (0/7) and in
the group with TP for technical or soft tissue-related
reasons (0/18). In summery the mortality in elective TP
was 6.25% (3/48). A statistically signiﬁcant diﬀerence was
found only between the “troubles” and “technical” groups,
P = .022.
3.6. Comparison between Total Pancreatectomy and the Rest
Pancreatic Resectional Procedures. A summary of the most
important characteristics of the four groups with total
pancreatectomy is given in Tables 1 and 2.T a b l e3 shows
a brief comparison of the morbidity and mortality in the
TP group versus all other pancreatic resections for the
studied period of time. There was no statistical diﬀerence
with regard to the rate of the most common major and
minor postoperative complications. There was a signiﬁcant
diﬀerence in the mortality rate. The postoperative hospital
stay was statistically longer in cases of TP (P = .001). The
annual number of TP performed at our center showed a
steady increase over the study period, which corresponded
to the increase in the total number of pancreatic procedures:
n = 2/98 in 2004 (2%), n = 11/162 in 2005 (6.8%), n =
12/220 in 2006 (5.5%), n = 20/301 in 2007 (6.6%). In the
ﬁrstsixmonthsof2008wereperformed18pancreatectomies
outof167pancreaticprocedures(10.8%).TherateofTPwas
signiﬁcantly higher in 2008 than in 2004 (10.8% versus 2%,
P = .008), however the rate of TP (n = 47/638, 7.4%) in the
second half of the study period (April 2006–June 2008) was
not higher than the rate (n = 16/310, 5.2%) in the ﬁrst half
(January 2004–March 2006), P = .214.
4. Discussion
In 1943/1944 Rocky [16] and Priestly et al. [17]d e m o n -
strated the feasibility of pancreatic resection in patients
with pancreatic cancer and hyperinsulinism. Ross [7]a n d
Porter [18] were early advocates of TP. They propagated that
TP should comprise the standard procedure for pancreatic
resection in order to avoid complications of pancreatic anas-
tomotic insuﬃciency. Furthermore the complete resection
of the gland oﬀered an elimination of multicentric disease
and the advantage of a wider lymphadenectomy in the
case of pancreatic cancer. Using this radical approach many
surgeons hoped to improve the overall survival in patients
with adenocarcinoma of the pancreas [19]. Several reports
demonstrated that TP can be performed safely [14, 15, 20]
and with the same morbidity as the standard Whipple
resection [8, 21]. In contrast, Trede [22] postulated the
complication rate of TP to be threefold higher compared to
pancreaticoduodenectomy. Some other studies also showed
a signiﬁcant higher morbidity and mortality in patients
who underwent TP in comparison to those who underwent
a less extensive resection [2, 23]. The main arguments
contra TP were the following metabolic consequences: (1)
endocrine insuﬃciency with a complete insulin deﬁciency
and the necessity of insulin therapy [24], (2) exocrine
insuﬃciency with steatorrhea and the need of durable
pancreatic enzyme replacement, (3) the development of
steatohepatis with progressive liver failure [25], and (4) the
lack of bicarbonate secretion with an increased risk for
the development of marginal and peptic ulcers resulting in
continuous application of proton pump inhibitors [24].
In 2003 B¨ uechler et al. [14] stated that TP has lost its
indication as pancreatic resections could be performed safely
with low complication rates. However referring on recent
study results M¨ uller et al. [15] partially revised this statemet
in 2007. They demonstrated that TP also can be performed
safely [12, 26] and underlined the clinical necessity to carry
out these operations in some well-selected indications.
In agree with this recent data of B¨ uechler et al. our
study has shown that TP is a demanding surgical procedure.
Nevertheless there exist a broad range of indications. We
present the data of 63 patients who underwent a TP
during the period of 54 months. Indications for TP were
analysed and classiﬁed in the “Four T’s”: Tumor, Trouble,
Technical diﬃculties and Therapy-refractory pain in patients
with chronic pancreatitis.
Size or localisation of pancreatic tumor can make TP
necessary in order to achieve a curative resection. In our
series locally advanced or multifocal pancreatic tumors
remain the most common indication for TP (40% of our
patients). Other examples for tumor-related indications are
recurrent pancreatic carcinoma, multicentric cancer [16,
27], intraductal papillary mucinous neoplasia (IPMN) with
invasive disease or diﬀuse involvement [3] of the gland,
and extensive neuroendocrine tumors [28, 29]. Although
all pancreatectomies in the “tumor group” were elective,
mortality was relatively high (13%). This may be explained
by the high rate of multivisceral resections 52% and vessel
reconstructions 17.4% in this group.
In all 15 patients of the “trouble group”, TP was either
an emergency procedure or an ultima ratio in ICU cases
(insuﬃciency of pancreatic anastomosis, pancreatic stump
insuﬃciency complicated by acute bleeding, necrosis of
pancreaticremnantfollowedbysepsis)inwhichconservative
therapy did not show any success. In those patients who
developed vessel arrosion due to insuﬃciency of pancreatic
anastomosis, acute bleeding occurred 5 to 14 days after
the initial operation. An early warning signal for imminent
vessel arrosion may be a permanent high inﬂammation
parameters with CRP values higher than 100mg/L. [30–32].
American Society of Anesthesiologists (ASA) classiﬁcation
of patients in the “trouble group” was III or IV. In these
patients surgery was very demanding due to the poor general
condition of these patients, adhesions, and the altered
intraoperative situs. The operation time was signiﬁcantly
shorter, but substantially intraoperative blood loss and
perioperative need of blood transfusions increased. This
group was characterized by the highest morbidity (73%)
and mortality (47%). Thus troubles represent disaster and
terrible reason for completion and it should be considered
alone as an “emergency” choice. Nevertheless only 3 patients
died following surgical complications of TP.
The majority of patients died due to medical complica-
tions (e.g., pneumonia, myocardial infection, arrhythmia).6 HPB Surgery
Table 1: Summary of data related to the four groups of patients who underwent total pancreatectomy (TP).
Group Number [%] Operative time [min] Blood loss [mL] RBC units Stay [days] Mortality [%]
(1) Tumors 23 (36.5%) 450 (360–750) 800 (300–2500) 0 (0–18) 20 (12–89) 3/23 (13%)
(2) Technical reasons 18 (28.6%) 445 (320–535) 600 (300–2200) 0 (0–4) 21 (10–108) 0/18 (0%)
(3) Troubles 15 (23.8%) 210 (120–525) 1500 (500–3000) 15 (0–34) 48 (22–90) 7/15 (47%)
(4) Therapy-refractory pancreatitis 7 (11.1%) 430 (350–480) 600 (300–2000) 0 (0–2) 15 (7–30) 0/7 (0%)
Median (min–max range) for all 63 patients: 420 (120–750) 800 (300–3000) 0 (0–34) 21 (7–108) 10/63 (15.9%)
Median (min–max range) for elective TP (48 patients): 440 (320–750) 800 (300–2500) 0 (0–18) 24 (11–109) 3/48 (6,25%)
∗For all parameters data are presented as median values with minimum-maximum range.
Table 2: Characteristics of 63 patients with total pancreatectomy
(TP).
Variable Tumors Technical
reasons Troubles
Therapyi-
resistant
pain
Number 23 18 15 7
Age (median
with
interquartile
range)
66
(62–72)
72.5
(65.5–77.25)
71
(64–75)
50
(46–58)
Gender
Male 10 13 6 5
Female 13 5 9 2
Histology
Cancer 20 15 5 0
Benign tumors 3 3 3 0
Chronic
pancreatitis 006 7
others 0 0 1 0
Primary TP 22 18 3 2
Completion TP 1 0 12 5
Portal vein/SMV
resection 901 2
S p l e n e c t o m y 2 061 4 5
Pylorus-
preserving
TP
61 79 5
Multivisceral
resection 401 3
Enzyme
replacement 211 7
Endocrine
insuﬃciency 353 6
ASA score
I1 0 0 0
II 13 5 2 4
III 8 12 13 2
IV 1 1 0 1
TP indicates total pancreatectomy; SMV: superior mesenteric vein; ASA:
American Society of Anesthesiologists.
In the reported series 18 TPs were performed because
of “technical diﬃculties”. In a soft and friable pancreatic
remnant that was unable to hold sutures sometimes a safe
pancreatic anastomosis was not possible. As 15 % of all
pancreatic ﬁstula can lead to a life-threatening haemorrhage
and sepsis in these cases, an elective TP was performed.
The aim of TP in this group was to avoid an emergency
completion pancreatectomy that is associated with a high
mortality rate (in our study: 47% cp. “trouble group”). There
was no perioperative or late mortality in this group. Until
today there exists no clear deﬁnition of a “soft” pancreas
and it remains to be elucidated which tissue characteristics
mandate removing the whole gland in the case of technical
problems. Deﬁnition of objective criteria and the attentive
evaluation of pros and cons are necessary to come to the
decision to carry out such a “prophylactic” procedure.
Another indication for TP is “therapy-refractory” pain.
Particularly, in patients with chronic pancreatitis, symptoms
not responding to medical treatment can remain or develop
again after drainage or resection surgery, indicating progress
of the disease or failure of the primary operative procedures,
respectively. Several studies demonstrated that only 30–60%
of patients with chronic pancreatitis experienced signiﬁcant
pain relief after resection surgery [4, 12]. In these patients TP
s o m e t i m e si si n e v i t a b l e[ 8–11]. In our collective 6 patients
(13%) underwent a TP because of chronic pancreatitis. In
5 patients a completion pancreatectomy was carried out
as reoperation following prior pancreatic surgery as, for
example, duodenum-preserving pancreatic head resection
(DPPHR).Inthisgroupasatisfactoryoutcomewasachieved.
Well-reﬂected and elective planned TP in these patients was
performed without any mortality and low morbidity. In
this context M¨ uller et al. [15] reported results of 147 TP
which correspond well to the ﬁndings of our study. 124
patients underwent elective TP and 23 patients completion
pancreatectomy for complications. Mortality in the elective
group was 4.8%, whereas it was 39.1% in the completion
TP group. Operation time of completion TP was signiﬁcant
higher than that in the elective group. Also the number
of transfused red blood count (RBC) units was signiﬁcant
higher. Surgical morbidity in the elective group was 24.2%;
in the completion TP group it reached 73.9%. Medical mor-
bidity was 14.5% and 56.5%, respectively [15]. These results
correspond with the data of our study. M¨ uller et al. [15]
reported an increasing demand for TP as 36% of patients
underwent TP in the last one of a ﬁve-year study period. The
number of TP in our collective also increased toward the end
of the study period. However this was basically caused by an
increased total number of pancreatic procedures that wereHPB Surgery 7
Table 3: Comparison of total pancreatectomy to other pancreatic resections.
Parameter Total pancreatectomy, n = 63 other pancreatic resections, n = 536 Statistical diﬀerence
Morbidity
erosion bleeding 3 (4.8%) 16 (3%) P = .447
biliary leakage 3 (4.8%) 8 (1.5%) P = .068
pancreatic leakage n.a. 25 (4.7%) n.a.
intraabdominal abscess 5 (7.9%) 26 (4.9%) P = .296
chylous ﬁstula 3 (4.8%) 21 (3.9%) P = .803
delayed gastric emptying 9 (14.3%) 41 (7.7%) P = .072
wound infection 4 (6.3%) 22 (4.2%) P = .409
Mortality in all 63 patients with TP 10 (15.9%) 6 (1.1%) P = .001
Mortality in elective TP (48 patients) 3 (6.25%) 6 (1.1%) P = .006
Postoperative hospital stay [days] 21 14 P = .001
∗n.a.: not applicable.
performed at our hospital. The following trend was observed
at our hospital: the number of TP for tumor and therapy-
refractory pain remained constant, the number of troubles-
TP decreased, and the number of TP by reason of technical
problems increased.
Several improvements in postoperative management
including treatment of diabetes mellitus and substitution
of pancreatic enzymes and fat-soluble vitamins have sig-
niﬁcantly reduced postoperative morbidity and improved
quality of life after TP. Recent studies described that there
was no signiﬁcant diﬀerence in quality of life in patients
with elective TP and partial pancreatectomy [15]. In this
context Billings et al. [33] also conﬁrmed no diﬀerence in
qualityoflifein34TPpatientscomparedwithtypeIdiabetic
controls. In addition pancreatic surgery has increased its
safety, especially at high-volume pancreas centres [15, 33–
36], and in future autoislet cell transplantation may oﬀer
another option to improve the outcome of patients receiving
TP leading to prolonged survival [37, 38].
In conclusion the reported literature and our data
exposed a satisfactory outcome for patients when the indica-
tion for TP was well reﬂected. We subdivided the indication
of TP into the “4 T’s”: Tumor, Therapy refractory pain,
Troubles, and Technical problems. Our data revealed, that
TP can be accomplished safely and with complication rates
comparablewithotherresectivepancreaticprocedures,when
it was performed by specialized and experienced surgeons.
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